biosimilars101

@biosimilars101

Providing factual, unbiased education and news about biosimilars to providers, patients, and their loved ones. RT ≠ Endorsement.

Vrijeme pridruživanja: prosinac 2016.

Tweetovi

Blokirali ste korisnika/cu @biosimilars101

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @biosimilars101

  1. prije 9 sati

    New review: the nocebo effect may contribute to treatment failures when patients are switched from an originator to a . Better patient education is among the authors' recommendations

    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Chronic diseases such as Rheumatoid Arthritis (RA) represent a lifelong burden on patients and their caregivers. adoption has the potential to broaden access to high-quality medicines for patients living with .

    Poništi
  3. Dr. Sarah Yim, Director of the Office of 's OTBB, hopes to see comparable robustness of the U.S. market to the European market in 10 years

    Poništi
  4. proslijedio/la je Tweet
    27. sij

    "Congress can — and should — do more to create a policy environment that is ripe for biosimilar adoption," says (D-NY) on the House floor on December 12. Watch for more:

    Poništi
  5. 4. velj

    education among physicians remains important, but the education of nurses should not be overlooked as a result, explains of

    Poništi
  6. 4. velj

    President and CEO of , , says a combination of perception, fearmongering, and lobbying initiatives has kept market penetration low compared to Europe

    Poništi
  7. 3. velj

    Report by : "['] sales in Europe continue to rapidly expand and robust cost savings have materialized." via

    Poništi
  8. 3. velj

    Where are the correct treatment option, providers' failure to prescribe them is a failure to address "financial toxicity," says in

    Poništi
  9. proslijedio/la je Tweet
    30. sij

    We applaud the 's draft guidance on interchangeable insulin. Greater competition from biosimilar insulins offers the promise of significant savings and increased access for diabetes patients. Read full comments:

    Poništi
  10. 31. sij

    Biosimilars present a "great opportunity" in community oncology," says Tesh Khulla, Senior VP and Advisor at

    Poništi
  11. 31. sij

    “There’s a lot of promise in the market going forward. We feel like the FDA is putting a good blueprint together, there seems to be legislation, and there are things that are very promising that will increase competition in the market.”

    Poništi
  12. proslijedio/la je Tweet
    23. sij

    : , COO of Pontchartrain Cancer Center: "The availability of introduces competition based on price, offering a lower-cost alternative in the short term and helping to restrict—or even reverse—longer-term price growth."

    Poništi
  13. 30. sij

    Kashyap Patel, MD says that ’ safety and efficacy have already been established--what is needed is intensive education in the U.S.

    Poništi
  14. proslijedio/la je Tweet
    22. sij

    bring better access and better health outcomes. A strong evidence base is the foundation of physician and patient confidence.

    Poništi
  15. 30. sij

    "In order for patients to have access to more affordable and , patent reform must be a priority in any policy aiming to prevent the prescription drug pricing crisis from getting any worse." Via

    Poništi
  16. 29. sij

    The soaring costs of drugs in the U.S. is largely a result of spending on specialty biologic agents. While many analysts including predict would curb spending, barriers remain says in an editorial. Via

    Poništi
  17. 29. sij

    Kashyap Patel, MD says his "biggest request" to manufacturers is that they use all possible avenues to raise awareness of the medicines among providers

    Poništi
  18. proslijedio/la je Tweet
    23. sij

    FDA-approved trastuzumab are expected to decrease the financial toxicity of treatment

    Poništi
  19. 28. sij

    : Some patients forego filling critically needed prescriptions, bypass diagnostic tests, and fail to make appointments with their providers due to the high cost of cancer care?

    Poništi
  20. 28. sij

    The FDA-approval of to treat breast cancer is expected to decrease the financial burden of treating the disease

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·